Esperion Therapeutics, Inc. (ESPR)

Esperion's stock experienced several notable events in the past six months. In November 2025, the company held a virtual investor KOL event focused on "Breaking the Statin Intolerance Barrier," and in January 2026, Esperion participated in the 44th Annual J.P. Morgan Healthcare Conference. In March 2026, updated ACC/AHA guidelines granted bempedoic acid several Class 1 recommendations, leading to a stock price increase and raised price targets from analysts. Esperion reported its fourth-quarter and full-year 2025 financial results on March 10, 2026, with revenue surpassing expectations. On April 2, 2026, Esperion Therapeutics announced the closing of its acquisition of Corstasis Therapeutics. Despite some positive developments, the stock has experienced fluctuations, with declines observed as of April 10, 2026, and in the week leading up to March 16, 2026.

While specific data on the seasonality of demand for Esperion Therapeutics' products is not explicitly detailed, the company has reported strong and consistent prescription demand and increasing physician adoption, driving durable revenue growth. The company is implementing new marketing initiatives to reach statin-intolerant patients and anticipates that the inclusion of bempedoic acid in clinical guidelines will lead to sustained usage. This suggests a focus on consistent growth rather than pronounced seasonal fluctuations.

Esperion Therapeutics is a biopharmaceutical company focused on developing and commercializing oral, non-statin medicines for patients at risk for cardiovascular disease due to elevated LDL-C. The company operates within the Healthcare sector, specifically in the Pharmaceutical and Specialty & Generic Drug Manufacturing industries, with a primary focus on cardiometabolic health. Its major products include NEXLETOL and NEXLIZET tablets, which are oral, once-daily, non-statin medicines designed to lower LDL-C and reduce cardiovascular risk. Esperion is also investing in research and development for triple-combination therapies and preclinical candidates.

Esperion Therapeutics is headquartered in Ann Arbor, Michigan, United States, and its products, NEXLETOL and NEXLIZET, are approved in the U.S. and Europe. The company has established international partnerships for the commercialization of its medicines, including with Daiichi Sankyo Europe for Europe and Otsuka Pharmaceutical Co., Ltd. for Japan. Neopharm Israel also filed a New Drug Application for marketing approval of NEXLETOL and NEXLIZET in Q1 2025.

Esperion's brand reputation has been positively influenced by its focus on addressing the unmet needs of patients with cardiovascular disease and the strong results from the CLEAR Outcomes trial. The updated ACC/AHA guidelines in March 2026, which granted bempedoic acid multiple Class 1 recommendations, also boosted its reputation. However, events such as a rival's announcement of Phase III CETP inhibitor results and a dispute with partner Daiichi Sankyo have had a negative impact on its reputation.

Esperion Therapeutics, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold 58.90% of the stock, Esperion Therapeutics insiders own 16.57%, and retail investors hold 24.53%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Two Seas Capital LP, Wasatch Advisors Inc, D. E. Shaw & Co., Inc., Orbimed Advisors Llc, State Street Corp, Geode Capital Management, Llc, Marshall Wace, Llp, and Two Sigma Investments, Lp. Target N. V. Biotech is noted as the largest individual Esperion Therapeutics shareholder, owning 1.74% of the company.